AR072395A1 - Formulacion de dosificacion solida de telcagepant potasico - Google Patents
Formulacion de dosificacion solida de telcagepant potasicoInfo
- Publication number
- AR072395A1 AR072395A1 ARP090102404A ARP090102404A AR072395A1 AR 072395 A1 AR072395 A1 AR 072395A1 AR P090102404 A ARP090102404 A AR P090102404A AR P090102404 A ARP090102404 A AR P090102404A AR 072395 A1 AR072395 A1 AR 072395A1
- Authority
- AR
- Argentina
- Prior art keywords
- oxo
- ppm
- solid dosage
- azepan
- imidazo
- Prior art date
Links
- 239000007787 solid Substances 0.000 title abstract 8
- CGDZXLJGHVKVIE-DNVCBOLYSA-N n-[(3r,6s)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-3h-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide Chemical compound FC1=CC=CC([C@H]2CN(CC(F)(F)F)C(=O)[C@H](NC(=O)N3CCC(CC3)N3C(NC4=NC=CC=C43)=O)CC2)=C1F CGDZXLJGHVKVIE-DNVCBOLYSA-N 0.000 title abstract 7
- 229950002563 telcagepant Drugs 0.000 title abstract 2
- 230000015572 biosynthetic process Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 7
- 229910052700 potassium Inorganic materials 0.000 abstract 5
- 239000011591 potassium Substances 0.000 abstract 5
- -1 2,3-difluorophenyl Chemical group 0.000 abstract 4
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 abstract 3
- 238000001237 Raman spectrum Methods 0.000 abstract 3
- HHFAWKCIHAUFRX-UHFFFAOYSA-N ethoxide Chemical compound CC[O-] HHFAWKCIHAUFRX-UHFFFAOYSA-N 0.000 abstract 3
- 238000001228 spectrum Methods 0.000 abstract 3
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 abstract 1
- 239000004475 Arginine Substances 0.000 abstract 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 1
- 239000008180 pharmaceutical surfactant Substances 0.000 abstract 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13354208P | 2008-06-30 | 2008-06-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR072395A1 true AR072395A1 (es) | 2010-08-25 |
Family
ID=41057505
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090102404A AR072395A1 (es) | 2008-06-30 | 2009-06-29 | Formulacion de dosificacion solida de telcagepant potasico |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20100009967A1 (enExample) |
| EP (1) | EP2303238A1 (enExample) |
| JP (2) | JP2011526909A (enExample) |
| KR (1) | KR20110025926A (enExample) |
| CN (1) | CN102076330A (enExample) |
| AR (1) | AR072395A1 (enExample) |
| AU (1) | AU2009267145A1 (enExample) |
| CA (1) | CA2728547A1 (enExample) |
| CR (1) | CR20110038A (enExample) |
| DO (1) | DOP2010000409A (enExample) |
| IL (1) | IL209833A0 (enExample) |
| MX (1) | MX2010014524A (enExample) |
| RU (1) | RU2011103170A (enExample) |
| SV (1) | SV2010003774A (enExample) |
| TW (1) | TW201004954A (enExample) |
| WO (1) | WO2010002763A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5243548B2 (ja) * | 2007-10-25 | 2013-07-24 | プロテウス デジタル ヘルス， インコーポレイテッド | 情報システムのための流体伝達ポート |
| EP2249833B1 (en) * | 2008-02-05 | 2012-10-17 | Merck Sharp & Dohme Corp. | Prodrugs of cgrp receptor antagonist |
| WO2017001434A1 (en) * | 2015-06-29 | 2017-01-05 | Galderma Research & Development | Cgrp receptor antagonist compounds for topical treatment of skin disorders |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2189698A (en) * | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated omeprazole tablets |
| ATE209491T1 (de) * | 1997-03-13 | 2001-12-15 | Hexal Ag | Stabilisierung von säureempfindluchen benzimidazolen unter verwendung von aminosäure/cyclodextrin kombinationen |
| US6174548B1 (en) * | 1998-08-28 | 2001-01-16 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
| JO2355B1 (en) * | 2003-04-15 | 2006-12-12 | ميرك شارب اند دوم كوربوريشن | Hereditary calcitonin polypeptide receptor antagonists |
| AU2007238896A1 (en) * | 2006-04-10 | 2007-10-25 | Merck Sharp & Dohme Corp. | CGRP antagonist salt |
| CA2662748A1 (en) * | 2006-09-08 | 2008-03-13 | Merck & Co., Inc. | Liquid pharmaceutical formulations for oral administration of a cgrp antagonist |
-
2009
- 2009-06-29 JP JP2011516753A patent/JP2011526909A/ja not_active Withdrawn
- 2009-06-29 AU AU2009267145A patent/AU2009267145A1/en not_active Abandoned
- 2009-06-29 RU RU2011103170/15A patent/RU2011103170A/ru not_active Application Discontinuation
- 2009-06-29 US US12/493,311 patent/US20100009967A1/en not_active Abandoned
- 2009-06-29 CN CN2009801252261A patent/CN102076330A/zh active Pending
- 2009-06-29 AR ARP090102404A patent/AR072395A1/es unknown
- 2009-06-29 WO PCT/US2009/049009 patent/WO2010002763A1/en not_active Ceased
- 2009-06-29 CA CA2728547A patent/CA2728547A1/en not_active Abandoned
- 2009-06-29 MX MX2010014524A patent/MX2010014524A/es not_active Application Discontinuation
- 2009-06-29 TW TW098121909A patent/TW201004954A/zh unknown
- 2009-06-29 EP EP09774214A patent/EP2303238A1/en not_active Withdrawn
- 2009-06-29 KR KR1020107029334A patent/KR20110025926A/ko not_active Withdrawn
-
2010
- 2010-12-07 IL IL209833A patent/IL209833A0/en unknown
- 2010-12-21 SV SV2010003774A patent/SV2010003774A/es not_active Application Discontinuation
- 2010-12-30 DO DO2010000409A patent/DOP2010000409A/es unknown
-
2011
- 2011-01-21 CR CR20110038A patent/CR20110038A/es not_active Application Discontinuation
- 2011-07-13 JP JP2011155043A patent/JP2011246478A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| MX2010014524A (es) | 2011-02-24 |
| CA2728547A1 (en) | 2010-01-07 |
| CN102076330A (zh) | 2011-05-25 |
| AU2009267145A1 (en) | 2010-01-07 |
| TW201004954A (en) | 2010-02-01 |
| EP2303238A1 (en) | 2011-04-06 |
| RU2011103170A (ru) | 2012-08-10 |
| CR20110038A (es) | 2011-03-16 |
| WO2010002763A1 (en) | 2010-01-07 |
| JP2011526909A (ja) | 2011-10-20 |
| JP2011246478A (ja) | 2011-12-08 |
| KR20110025926A (ko) | 2011-03-14 |
| IL209833A0 (en) | 2011-02-28 |
| US20100009967A1 (en) | 2010-01-14 |
| SV2010003774A (es) | 2011-03-23 |
| DOP2010000409A (es) | 2011-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2020000062A (es) | Procedimiento para la preparación de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}metilcarbamato de metilo y su purificación para el uso como principio activo farmacéutico | |
| IL234272B (en) | The mesosulfate salt of n – (r9, s6, s5) – 5 amino – 6 – (2, 3 – difluorophenyl) – 6, 7, 8, 9, – tetrahydro – h5 – cyclohepta [b] pyridine – 9 – yl – 4 – (2-oxo-2,3,dihydro-h1-imidazo[5,4-b]pyridine-1-yl)piperidine-1-carboxylate | |
| PE20130779A1 (es) | Pirimidinas y triazinas condensadas y su uso | |
| CR20110343A (es) | Inhibidores de proteína cinasa | |
| EP2580213A4 (en) | 8- (HETEROARYLMETHYL) PYRIDO [2,3-D] PYRIMIDIN-7 (8H) -ONES FOR THE TREATMENT OF CNS DISORDERS | |
| WO2011156646A3 (en) | 6-(sulfonylaryl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders | |
| IN2014CN04174A (enExample) | ||
| CL2009000957A1 (es) | Compuestos derivados de pirrolo[2,3-d]pirimidina; inhibidores de limk2; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos inflamatorios, glaucoma, neurodegeneracion, entre otras. | |
| AR077144A1 (es) | Derivado de fenilimidazol como inhibidor de la enzima pde10a, composiciones farmaceuticas y uso de los mismos en el tratamiento de trastornos neurodegenerativos y psiquiatricos | |
| TN2012000259A1 (en) | Method for producing methyl-{4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridino-3-yl]pyrimidino-5-yl} carbamate and its purification for use thereof as pharmaceutical substance | |
| UA108711C2 (uk) | Сполуки триазолопіридину як інгібітори фосфодіестерази pde10a | |
| CR20110093A (es) | [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-[7-fluoro-1-(2-metoxi-etil)-4-trifluorometoxi-1h-indol-3-il]-metanona como un inhibidor de la triptasa de mastocitos | |
| CL2012000263A1 (es) | Compuestos derivados de amidas espiro ciclica, agonista b-adrenoreceptor y antagonista muscarinico; utiles en el tratamiento en enfermedades inflamatorias, tales como epoc. | |
| DE602007012313D1 (de) | Als a2b-adenosinrezeptorantagonisten geeignete 5-phenyl-6-pyridin-4-yl-1,3-dihydro-2h-imidazoä4,5-büpyridin-2-onderivate | |
| CL2010000281A1 (es) | Formulacion oral en forma de tableta de 9-[(2,2-dimetil-propilamino)-metil]-minociclina; metodo de preparacion; formulacion inyectable del mismo; utiles en el tratamiento de una infeccion. | |
| AR072395A1 (es) | Formulacion de dosificacion solida de telcagepant potasico | |
| WO2014053968A8 (en) | Pyrrolo[3,2-c]pyridine tropomyosin-related kinase inhibitors | |
| PE20150965A1 (es) | Azaindolinas | |
| CL2013003567A1 (es) | Forma cristalina anhidra de {(s)-3-[6-(6-metoxi-5-metil-piridin-3-il)-5,6,7,8-tetrahidro-pirido[4,3-d]pirimidin-4-iloxi]-pirrolidin-1-il}-(tetrahidro-piran-4-il)-metanona, sales de la misma; composicion farmaceutica; combinacion farmaceutica; uso en el tratamiento de trastornos autoinmunes, inflamatorios, alergicos, rechazo de trasplantes, entre otros. | |
| MY165623A (en) | 7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin d2 receptor modulators | |
| CL2015001409A1 (es) | Forma cristalina anhidra de (1,1-dioxo-hexahidro-1lambda*6*-tiopiran-4-il)-{(s)-3-[1-(6-metoxi-5-metil-piridin-3-il)-2,3-dihidro-1h-pirido[3,4-b][1,4]oxazin-7-iloxi]-pirrolidin-1-il}-metanona; composicion farmaceutica; uso en el tratamiento de trastornos autoinmunes, inflamatorios, alergicos, rechazo de trasplantes, entre otros. | |
| PE20141945A1 (es) | Derivados de quinolina como inhibidores de la enzima pde10a | |
| TN2010000572A1 (en) | Solid dosage formulations of telcagepant potassium | |
| UY31020A1 (es) | 2-amino-7,8-dihidro-6h-pirido[4,3-d]pirimidina-5-onas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |